Candel Therapeutics an off-the-shelf multimodal biological immunotherapy company empowering the patient's immune system to fight cancer.
Joined January 2019
- Tweets 625
- Following 151
- Followers 771
- Likes 170
523 Photos and videos
Jun 12
Our CEO @paulpetertak will moderate the "Existing Pipelines: Maintaining Clinical Progress" panel at the
@LongwoodLeaders MIT CEO forum, on June 16.
longwoodhealthcareleaders.co…
#MITCEO #Biotech #Biopharma $CADL
2
7
322
Our CEO @paulpetertak spoke with @endpts reporter @Nicole_DeFeudis about new long-term follow-up data from our phase 3 trial of aglatimagene besadenovec (CAN-2409) in localized #ProstateCancer.
endpoints.news/candel-report…
$CADL #Immunotherapy #CancerResearch
2
4
22
1,107
Our pivotal phase 3 trial of aglatimagene besadenovec (CAN-2409) in localized prostate cancer is now published in @TheLancetOncol. 80.4% of treated patients achieved pathological complete response in 2-year biopsies vs. 63.6% on placebo.
ir.candeltx.com/news-release…
$CADL
1
5
30
1,012
May 29
Kyle Donahue's 5-year journey with glioblastoma, featured in @ParadeMagazine, shows the potential of innovative treatments. After enrolling in our linoserpaturev (CAN-3110) trial, her tumors shrank and she’s regained much of her life.
parade.com/health/kyle-donah…
#Glioblastoma $CADL
4
20
894
May 27
We are heading to the Jefferies Global Healthcare Conference in New York, sharing updates across our pipeline in prostate cancer, NSCLC, glioma, and our enLIGHTEN™ Discovery Platform.
ir.candeltx.com/news-release…
@paulpetertak #Biotech #Biopharma $CADL
3
27
813
May 26
We’ll be in Chicago for @ASCO!
Our team is available for meetings — reach out to connect and hear updates on our pipeline.
candeltx.com/
#ASCO26 #Oncology #CancerResearch $CADL
2
1
12
1,351
May 21
Our CTDO Seshu Tyagarajan, Ph.D., discusses the analytical and validation work underpinning our BLA submission for aglatimagene besadenovec with @Lifesci_Connect, including our in-house QC capabilities and potency testing strategy.
cellandgene.com/doc/validati…
#Biotech $CADL
2
4
20
680
May 20
On #ClinicalTrialsDay, we are grateful to the patients, investigators, and healthcare professionals driving progress in cancer care.
Learn more about our clinical programs: candeltx.com/patients/
#CancerResearch #Immunotherapy $CADL
1
14
390
May 19
Our CEO @paulpetertak is presenting at the Stifel 2026 Virtual Targeted Oncology Forum, sharing updates across our pipeline in prostate cancer, NSCLC, and recurrent glioma.
ir.candeltx.com/news-release…
#Oncology #Biotech $CADL
1
2
16
613
May 15
Announced Today - New extended follow-up data from our phase 3 trial of aglatimagene besadenovec (CAN-2409) in localized prostate cancer presented today at #AUA26.
Details here: ir.candeltx.com/news-release…
#ProstateCancer #Immunotherapy $CADL
3
4
22
912
May 14
Today we announced our Q1 2026 financial results and provided corporate updates on our development programs.
Full details: ir.candeltx.com/news-release…
$CADL
1
3
16
582
May 13
Proud to see our Chief Regulatory Officer Susan Stewart, J.D., spotlighted in @RAPSorg 50 for 50, honoring outstanding regulatory professionals for its 50th anniversary. Her expertise continues to be invaluable in guiding our regulatory strategy at Candel.
inform.raps.org/50-for-50
2
2
24
642
May 11
This #NationalCancerResearchMonth, we are proud to be advancing multimodal viral immunotherapies across prostate cancer, NSCLC, and recurrent glioblastoma, with key milestones ahead in 2026.
candeltx.com/pipeline/
#CancerResearch #Immunotherapy $CADL
1
2
23
692
We are heading to #AUA26!
Join us for new extended follow-up data from our phase 3 trial of aglatimagene in localized #prostatecancer, presented by Dr. Mark Garzotto in a plenary session.
Visit our booth to connect with our team.
ir.candeltx.com/news-release…
@AmerUrological
2
16
456
We will host a conference call on May 15 to discuss extended phase 3 data for aglatimagene besadenovec in localized #ProstateCancer, with thought leaders Dr. Daniel George, Dr. Neal Shore, and Dr. Jonathan Tward.
Registration details: ir.candeltx.com/news-release…
#AUA2026 $CADL
1
3
23
892
At #BioEquityEurope, our CEO @paulpetertak presented phase 2 data for aglatimagene in advanced NSCLC.
50% of patients survived beyond 24 months despite prior immune checkpoint inhibitor failure, with a long-term survival tail supporting phase 3 initiation.
@BioCentury #CADL
2
3
26
701
At #BioEquityEurope, our CEO @paulpetertak joined a panel on Patient Engagement Strategies, discussing how the patient perspective should shape innovation in drug discovery and development.
conferences.biocentury.com/b…
@BioCentury #PatientEngagement #PatientFirst #Biotech $CADL
1
1
19
538
We are presenting at BioEquity Europe 2026 in Prague!
Connect with our team to learn more about our viral immunotherapy pipeline across prostate cancer, NSCLC, and glioma.
conferences.biocentury.com/b…
@paulpetertak @BioCentury
#ProstateCancer #Immunotherapy $CADL
2
4
20
706
Our CEO @paulpetertak, M.D., Ph.D., and CTDO Seshu Tyagarajan, Ph.D., discuss our sprint to BLA submission for aglatimagene besadenovec (CAN-2409) with @Lifesci_connect, covering our partner-led manufacturing strategy and commercial readiness.
cellandgene.com/doc/mapping-…
$CADL
5
3
18
854
Apr 29
Today we announced a commercialization agreement with @EVERSANA to support potential U.S. launch of aglatimagene besadenovec (CAN-2409) for localized #ProstateCancer, ahead of our planned BLA submission in Q4 2026.
ir.candeltx.com/news-release…
$CADL
2
2
22
812